Merck's Pipeline Story Drives 85% Stock Surge

Merck's stock price surged by around 85% between July 2025 and July 2026, outperforming both its large-cap pharmaceutical peers and the S&P 500. To understand this remarkable growth, it is essential to examine the company's pipeline story and how management laid out a blueprint for a transformed business.

The financials appeared to indicate slowing sales, with trailing-twelve-month revenue growth decelerating to 1.8% as of its fiscal Q2 2025 report, down from a three-year average of 3.7%. However, executives were painting a different picture through their earnings calls, discussing a potential commercial opportunity exceeding $50 billion from around '20 promising new growth drivers.'

The first major domino to fall was the positive top-line results from Phase III trials for enlicitide, Merck's oral PCSK9 inhibitor for cholesterol, announced in mid-2025. This breakthrough transformed the company's pipeline story into hard data, providing a crucial 'proof point' that bolstered management's confidence.

The options market seemed to be pricing in a significant move, with implied volatility hovering around the 70th percentile of its one-year range before the surge. The central question for Merck has long been whether its pipeline could offset the eventual decline of its biggest drug, KEYTRUDA.